Literature DB >> 24687822

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

César Serrano1, Yuexiang Wang2, Adrián Mariño-Enríquez2, Jen-Chieh Lee3, Gloria Ravegnini4, Jeffrey A Morgan5, Monica M Bertagnolli2, Carol Beadling6, George D Demetri5, Christopher L Corless7, Michael C Heinrich6, Jonathan A Fletcher8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24687822      PMCID: PMC4559610          DOI: 10.1200/JCO.2013.48.7488

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

1.  Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.

Authors:  Markku Miettinen; John F Fetsch; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-01       Impact factor: 6.394

2.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Authors:  Katherine A Janeway; Su Young Kim; Maya Lodish; Vânia Nosé; Pierre Rustin; José Gaal; Patricia L M Dahia; Bernadette Liegl; Evan R Ball; Margarita Raygada; Angela H Lai; Lorna Kelly; Jason L Hornick; Maureen O'Sullivan; Ronald R de Krijger; Winand N M Dinjens; George D Demetri; Cristina R Antonescu; Jonathan A Fletcher; Lee Helman; Constantine A Stratakis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

3.  BRAF mutation status in gastrointestinal stromal tumors.

Authors:  Isabelle Hostein; Nicolas Faur; Charlotte Primois; Frédérique Boury; Jérome Denard; Jean-François Emile; Pierre-Paul Bringuier; Jean-Yves Scoazec; Jean-Michel Coindre
Journal:  Am J Clin Pathol       Date:  2010-01       Impact factor: 2.493

4.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

5.  Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age.

Authors:  Markku Miettinen; Zeng-Feng Wang; Maarit Sarlomo-Rikala; Czeslaw Osuch; Piotr Rutkowski; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

6.  Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

Authors:  Ann W Gramza; Christopher L Corless; Michael C Heinrich
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

7.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Authors:  Filip Janku; Jennifer J Wheler; Aung Naing; Gerald S Falchook; David S Hong; Vanda M Stepanek; Siqing Fu; Sarina A Piha-Paul; J Jack Lee; Rajyalakshmi Luthra; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Cancer Res       Date:  2012-10-12       Impact factor: 12.701

8.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Authors:  B Liegl; I Kepten; C Le; M Zhu; G D Demetri; M C Heinrich; C D M Fletcher; C L Corless; J A Fletcher
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

9.  Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Authors:  Narasimhan P Agaram; Grace C Wong; Tianhua Guo; Robert G Maki; Samuel Singer; Ronald P Dematteo; Peter Besmer; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2008-10       Impact factor: 5.006

10.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

View more
  16 in total

1.  New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.

Authors:  Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-01

Review 2.  What is New in Gastrointestinal Stromal Tumor?

Authors:  Inga-Marie Schaefer; Adrián Mariño-Enríquez; Jonathan A Fletcher
Journal:  Adv Anat Pathol       Date:  2017-09       Impact factor: 3.875

Review 3.  Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

Authors:  César Serrano; Suzanne George; Claudia Valverde; David Olivares; Alfonso García-Valverde; Cristina Suárez; Rafael Morales-Barrera; Joan Carles
Journal:  Target Oncol       Date:  2017-06       Impact factor: 4.493

Review 4.  New treatment strategies for advanced-stage gastrointestinal stromal tumours.

Authors:  Lillian R Klug; Homma M Khosroyani; Jason D Kent; Michael C Heinrich
Journal:  Nat Rev Clin Oncol       Date:  2022-02-25       Impact factor: 66.675

Review 5.  Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.

Authors:  Yang Yang; Shuo Li; Yujiao Wang; Yi Zhao; Qiu Li
Journal:  Signal Transduct Target Ther       Date:  2022-09-17

6.  Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.

Authors:  Wen-Bin Ou; Nan Ni; Rui Zuo; Weihao Zhuang; Meijun Zhu; Anastasios Kyriazoglou; Duolin Wu; Grant Eilers; George D Demetri; Haibo Qiu; Bin Li; Adrian Marino-Enriquez; Jonathan A Fletcher
Journal:  Oncogene       Date:  2019-08-01       Impact factor: 9.867

Review 7.  Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Authors:  Adrián Mariño-Enríquez; Judith V M G Bovée
Journal:  Surg Pathol Clin       Date:  2016-09

8.  Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.

Authors:  Jerzy Lasota; Anna Felisiak-Golabek; Bartosz Wasag; Artur Kowalik; Sebastian Zięba; Małgorzata Chłopek; Zeng-Feng Wang; Tiffany Coates; Janusz Kopczynski; Stanislaw Gozdz; Maarit Sarlomo-Rikala; Markku Miettinen
Journal:  Mod Pathol       Date:  2016-01-22       Impact factor: 7.842

Review 9.  Liquid Biopsy in Gastrointestinal Stromal Tumors: Ready for Prime Time?

Authors:  David Gómez-Peregrina; Alfonso García-Valverde; Daniel Pilco-Janeta; César Serrano
Journal:  Curr Treat Options Oncol       Date:  2021-02-27

Review 10.  New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.

Authors:  César Serrano; Sebastian Bauer
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.